-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The public information shows that the Fc-mediated and complement-mediated ability function of the candidate drug Pai Ampri is completely removed by the Fc region mutation, and has the characteristics of slow antigen binding dissocation rate.
these characteristics make Pianpre more effective in blocking PD-1 pathfour activity and maintaining stronger T-cell anti-tumor activity, potentially becoming a better clinically-advantaged anti-PD-1 drug.
May, the NDA used by Paianpree to treat at least a second-line system chemotherapy relapse or recurring (r/r) classic Hodgkin's lymphoma (r/r cHL) was accepted by the NMPA.
Pai Anpley Single Resistance was jointly developed and commercialized by a joint venture established by Kangfang Bio and Zhengda Tianqing, a subsidiary of China Biopharmaceuticals.
According to the press release, Pianpri is the only new drug available for the development of single or combination therapies based on PD-1 antibodies in China, and is one of the candidates for PD-1 monoclonal antibodys in the late stages of clinical development, differentiated and possibly best-in-class.
According to the Drug Clinical Trial Registration and Information Disclosure Platform, Pampley is currently conducting a number of clinical trials involving a variety of cancers including liver, stomach, lung, classic Hodgkin's lymphoma, and advanced head and neck chest tumors.
: The registered clinical trial for the treatment of third-line nasopharyngeal cancer reached its main endpoint. Retrieved Oct 12, 2020, from #rd Source: Supplied.